(Q47917346)

English

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys.

scientific article published on 24 October 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Plasmodium falciparum

1 reference

based on heuristic

inferred from title

Elke S Bergmann-Leitner

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Marie-Claude Dubois

16

object named as

M C Dubois

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

11

object named as

E Angov

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

D. Gray Heppner

19

object named as

D G Heppner

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

S Pichyangkul

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

P Tongtawe

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

U Kum-Arb

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

K Yongvanitchit

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M Gettayacamin

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M R Hollingdale

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

A Limsalakpetch

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

V A Stewart

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

D E Lanar

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

S Dutta

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

L A Ware

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

B House

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

G Voss

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

J D Cohen

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

M M Fukuda

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

R S Miller

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

language of work or name

0 references

publication date

24 October 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

452-462

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Induction in humans of CD8+ and CD4+ T cell and antibody responses by sequential immunization with malaria DNA and recombinant protein.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Safety, tolerability, and antibody responses in humans after sequential immunization with a PfCSP DNA vaccine followed by the recombinant protein vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The nature and consequences of intra- and inter-vaccine interference

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Enhanced protection against malaria by a chimeric merozoite surface protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Development, characterization and immunogenicity of a multi-stage, multi-valent Plasmodium falciparum vaccine antigen (FALVAC-1A) expressed in Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Reduced immunogenicity of DNA vaccine plasmids in mixtures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Special Report: The 1996 Guide for the Care and Use of Laboratory Animals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Profiling the antibody immune response against blood stage malaria vaccine candidates.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Proteolytic processing and primary structure of Plasmodium falciparum apical membrane antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Towards a blood-stage vaccine for malaria: are we following all the leads?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immune responses to asexual blood-stages of malaria parasites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Deletion of Plasmodium berghei-specific CD4+ T cells adoptively transferred into recipient mice after challenge with homologous parasite

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Apoptotic deletion of Th cells specific for the 19-kDa carboxyl-terminal fragment of merozoite surface protein 1 during malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The mechanism and significance of deletion of parasite-specific CD4(+) T cells in malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Dendritic cells, pro-inflammatory responses, and antigen presentation in a rodent malaria infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Pathology of Plasmodium chabaudi chabaudi infection and mortality in interleukin-10-deficient mice are ameliorated by anti-tumor necrosis factor alpha and exacerbated by anti-transforming growth factor beta antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

The immunogenicity and reactogenicity of DTPw-HBV/Hib 2.5 combination vaccine: results from four phase III multicenter trials across three continents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Immunogenicity of a Haemophilus influenzae type b-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Dimorphic Plasmodium falciparum merozoite surface protein-1 epitopes turn off memory T cells and interfere with T cell priming.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Antibody-independent immunity to reinfection malaria in B-cell-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.022

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2009.10.022

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19857448%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47917346&oldid=1775328998"